MedTrace Logo

Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer

NCT03086785 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2018-01-17

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy and safety of patients who receive apatinib single or combined capecitabine for treatment of patients with metastatic her-2 negative breast cancer.

Conditions

  • Breast Cancer Metastatic

Interventions

DRUG

Apatinib

apatinib 500mg qd po or combined capecitabine 1000mg/m2 bid d1-14 q3w

Sponsors & Collaborators

  • Hebei Medical University Fourth Hospital

    lead OTHER

Principal Investigators

  • cuizhi Geng, archiat · Hebei Medical University Fourth Hospital

  • zefei Jiang, archiat · The 307th Hospital of Chinese Peoples' Liberation Army

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-24
Primary Completion
2018-11-30
Completion
2019-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03086785 on ClinicalTrials.gov